ImmunityBio IBRX
NASDAQ IBRX
$8.07 -0.11 (-1.40%)
As of: Sep 4, 2026 · 3:59 PM EDT

ImmunityBio (IBRX) Gross Profit Growth (1y) (2024 - 2026)

Analysis

ImmunityBio (IBRX) Gross Profit Growth (1y) (2024 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gross Profit Growth (1y) (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 11.24%
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 15.59%
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 63.51%
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 126.09%
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 33.01%
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 57.16%
8 Royalty Pharma 28.45 Bn 27.61 Bn - -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 351.57%
10 ImmunityBio 8.51 Bn 8.15 Bn 50.94 Mn 93.78%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 93.78%
Mar 31, 2026 167.14%
Dec 31, 2025 401.89%
Sep 30, 2025 422.17%
Jun 30, 2025 2,410.89%
Mar 31, 2025 41,047.50%
Dec 31, 2024 5,333.09%
Sep 30, 2024 7,346.34%
Jun 30, 2024 2,453.66%